Today: 10 June 2026
Browse Category

NYSE:PFE 7 February 2026 - 9 June 2026

Pfizer Falls in Premarket; Fresh FDA Approval Not Lifting the Stock

Pfizer Falls in Premarket; Fresh FDA Approval Not Lifting the Stock

Pfizer shares fell 1.7% premarket to $25.62 as investors weighed an FDA label expansion for hemophilia drug Hympavzi—now the first subcutaneous non-factor therapy for children 6-11 with hemophilia B—against slower progress in obesity drugs, with mid-stage data for weight-loss shot berobenatide showing a 23.3% vomiting rate and no immediate growth catalyst for the $147 billion company.
9 June 2026
··
Pfizer Stock Had a Quiet Week. Its Cancer Pipeline Just Got Loud

Pfizer Stock Had a Quiet Week. Its Cancer Pipeline Just Got Loud

Pfizer faces a key market test Monday after unveiling new cancer drug data at ASCO and a China partnership worth up to $10.5 billion. Friday’s close: $26.18, up 0.15%. Braftovi nearly doubled progression-free survival in metastatic colorectal cancer; Talzenna plus Xtandi cut prostate cancer risk by 52%. Seven-year Lorbrena data showed 55% of lung cancer patients alive without progression. Innovent deal flagged for early-stage risk.
31 May 2026
·
Pfizer Faces Busy Week After Friday’s Drop

Pfizer Faces Busy Week After Friday’s Drop

Pfizer shares closed at $25.33 Friday, down 1.63%, underperforming the S&P 500, which fell 1.24% but still posted a weekly gain. The company reaffirmed its 2026 revenue and earnings guidance after first-quarter revenue rose 5% to $14.45 billion. Investors remain cautious, citing competitive pressure from Eli Lilly and uncertainty over Pfizer’s pipeline. U.S. markets reopen Monday.
17 May 2026
···
Pfizer Inc Looks to India, but Investors Hold Off

Pfizer Inc Looks to India, but Investors Hold Off

Pfizer is increasing investment in India for cancer drugs, obesity treatments, and vaccines as it seeks growth beyond COVID-era sales. The company reported Q1 revenue of $14.5 billion, up 5%, but expects a $1.5 billion hit this year from generic competition. Shares fell 1.8% to $25.29 in New York trading. In Europe, Pfizer won expanded approval for its hemophilia drug Hympavzi.
15 May 2026
·
Pfizer Stock Faces a Fresh COVID Patent Overhang as Investors Wait for Its Next Growth Act

Pfizer Stock Faces a Fresh COVID Patent Overhang as Investors Wait for Its Next Growth Act

A Delaware federal judge dismissed Acuitas Therapeutics’ attempt to clear Pfizer and BioNTech’s Comirnaty vaccine from GSK patent claims, citing lack of jurisdiction. The ruling does not address whether Comirnaty infringes GSK’s patents. Pfizer shares last closed at $25.68, down 1.42%. The company reaffirmed 2026 revenue guidance and reported first-quarter revenue of $14.5 billion.
11 May 2026
··
Novavax Stock Jumps As Pfizer Deal Cash Puts Vaccine Turnaround Back In Focus

Novavax Stock Jumps As Pfizer Deal Cash Puts Vaccine Turnaround Back In Focus

Novavax shares jumped 13% Friday after first-quarter revenue reached $139.5 million, beating estimates. Licensing and partner payments, including $30 million from Pfizer’s Matrix-M deal, offset weak COVID-19 vaccine demand. The stock traded at $10.45 with volume over 8.4 million shares. Investors await the company’s appearance at BofA’s health-care conference on May 13.
8 May 2026
···
Pfizer Earnings Beat Wall Street, But The Patent Cliff Is Still The Story

Pfizer Earnings Beat Wall Street, But The Patent Cliff Is Still The Story

Pfizer posted first-quarter adjusted earnings of 75 cents per share on $14.45 billion in revenue, beating Wall Street forecasts. Sales of Eliquis and Padcev rose, offsetting steep declines in COVID products. The company maintained its 2026 revenue and profit outlook. Research and development expenses increased 12% as Pfizer invested in oncology and obesity drugs.
5 May 2026
···
Pfizer Stock in Focus After FDA Priority Review as Padcev, Obesity Bets Drive Post-COVID Reset

Pfizer Stock in Focus After FDA Priority Review as Padcev, Obesity Bets Drive Post-COVID Reset

The FDA granted priority review to Pfizer and Astellas’ Padcev for muscle-invasive bladder cancer, setting an Aug. 17 decision date. Pfizer shares rose 0.8% to $27.78 after the news. The company reports first-quarter results May 5, with investors watching oncology and obesity drugs to offset declining COVID sales and loss of exclusivity on older products.
20 April 2026
··
Pfizer Stock Faces Fresh Questions as Aberdeen, Stratos and Raab & Moskowitz Trim Stakes

Pfizer Stock Faces Fresh Questions as Aberdeen, Stratos and Raab & Moskowitz Trim Stakes

Aberdeen Group, Raab & Moskowitz Asset Management, and Stratos Wealth Partners sold a combined 740,174 Pfizer shares in the fourth quarter, according to recent 13F filings. Pfizer stock traded down 0.7% at $28.12 Monday. The three firms still held about $140.9 million in Pfizer shares at year-end. Pfizer halted a major U.S. COVID shot study after the period covered by the filings.
6 April 2026
··
Is Pfizer Stock a Buy? Shares Hit Fresh High as Bulls and Bears Clash Over Valuation

Is Pfizer Stock a Buy? Shares Hit Fresh High as Bulls and Bears Clash Over Valuation

Pfizer shares hit a 52-week high of $28.30 in New York Tuesday, lifted by recent drug pipeline updates and strong fourth-quarter sales. The company reported Q4 revenue of $17.56 billion and reaffirmed 2026 guidance. Some analysts remain cautious, with Acquirer’s Multiple valuing shares at $14–$15. Recent trial data showed positive results for Talzenna in prostate cancer and atirmociclib in breast cancer.
31 March 2026
··
Pfizer Stock Price Today: Shares Slip After GSK RSV Move Offsets Eliquis Data

Pfizer Stock Price Today: Shares Slip After GSK RSV Move Offsets Eliquis Data

Pfizer shares closed down 1% at $26.60 Friday after GSK’s RSV vaccine won expanded FDA approval for at-risk adults 18 to 49, narrowing Pfizer’s lead in the RSV market. Positive trial data for Pfizer’s blood thinner Eliquis offset some pressure, but the stock finished near session lows amid broader market weakness and uncertainty over the company’s near-term growth outlook.
13 March 2026
···
Pfizer Stock Price Today: PFE Falls 1.6% but Stays Near 52-Week High (MarketWatch)

Pfizer Stock Price Today: PFE Falls 1.6% but Stays Near 52-Week High (MarketWatch)

Pfizer shares fell 1.6% to $26.86 Thursday amid a broad U.S. market selloff as oil prices rose on Middle East tensions. The company faces pressure from declining COVID product sales and forecast 2026 profit below Wall Street estimates. China approved Pfizer’s GLP-1 weight-loss drug last week, while rival Eli Lilly announced a $3 billion China investment. Pfizer lost a legal bid in generic-drug litigation this week.
12 March 2026
···
Johnson & Johnson Moves Tecvayli Earlier in Europe After FDA Myeloma Nod

Johnson & Johnson Moves Tecvayli Earlier in Europe After FDA Myeloma Nod

Johnson & Johnson filed with the European Medicines Agency to expand Tecvayli’s use as a solo treatment for adults with relapsed or refractory multiple myeloma after one prior therapy. The filing follows U.S. approval of Tecvayli with Darzalex last week and is supported by a phase 3 trial showing Tecvayli reduced disease progression or death by 71% versus standard care.
10 March 2026
···
Pfizer stock slips before the open after a run to $27.73 — here’s what’s driving PFE now

Pfizer stock slips before the open after a run to $27.73 — here’s what’s driving PFE now

Pfizer shares slipped 0.3% to $27.52 in premarket trading Wednesday after a 2.1% gain the previous session. The company agreed to a $29 million settlement with the SEC over a 2013 insider-trading case tied to SAC Capital, pending court approval. Pfizer joined Swiss biotech incubator BaseLaunch as a partner. Investors await Friday’s U.S. consumer price index report.
11 February 2026
···
1 2 3 … 10

Stock Market Today

  • Palantir Technologies Advances AI Data Solutions, Impacting PLTR Stock
    June 10, 2026, 11:11 AM EDT. Palantir Technologies Inc. is expanding its AI infrastructure with its AI Platform (AIP), aiming to enhance governed AI return on investment (ROI) beyond initial token expenditures. This development reflects Palantir's strategy to solidify its position as a leader in data integration and analytics for artificial intelligence applications. Investors should monitor PLTR stock as the company scales AI offerings, potentially influencing its market performance amid growing demand for AI-driven data solutions.

Latest articles

Chewy Drops After Q1 Beat With Outlook Warning

Chewy Drops After Q1 Beat With Outlook Warning

10 June 2026
Chewy slashed its 2026 net sales outlook to $13.40–$13.55 billion, below prior guidance and analyst estimates, sending shares down 50 cents to $19.90 as investors reacted to weaker-than-expected second-quarter forecasts despite a 7.7% first-quarter sales jump and improved profitability.
Nu Holdings Stock Moves Higher, Investors Weigh $1 Billion Buyback Impact

Nu Holdings Stock Moves Higher, Investors Weigh $1 Billion Buyback Impact

10 June 2026
Nu Holdings stock rebounded 1.3% to $12.04 early Wednesday after a $1 billion buyback was authorized, but shares remain down 30.5% over six months as investors weigh the buyback’s support against rising credit costs, a CFO transition that triggered analyst downgrades, and a jump in non-performing loans to 5.0% last quarter.
Keel Infrastructure Inches Up After $458M Debt Deal Amid AI Pivot

Keel Infrastructure Inches Up After $458M Debt Deal Amid AI Pivot

10 June 2026
Keel Infrastructure jumped 0.83% to $5.47 after closing a $458 million convertible-note sale, up from an initial $350 million plan, with proceeds aimed at AI data-center growth and capped calls to limit dilution up to $11.86 per share, as investors weigh new capital against added debt and future share issuance.
Go toTop